Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.02 Average PT from Analysts

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been given an average rating of "Hold" by the seven analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $4.02.

SGHT has been the subject of several analyst reports. Lake Street Capital raised their price objective on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research note on Friday, May 9th. Citigroup reissued a "neutral" rating and issued a $3.60 price objective (up previously from $3.20) on shares of Sight Sciences in a research note on Thursday, May 22nd. Stifel Nicolaus decreased their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Piper Sandler decreased their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th.

Insiders Place Their Bets

In other news, CEO Paul Badawi sold 24,174 shares of Sight Sciences stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now directly owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were bought at an average price of $2.73 per share, with a total value of $27,300.00. Following the completion of the purchase, the executive vice president now directly owns 145,000 shares of the company's stock, valued at approximately $395,850. This trade represents a 7.41% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 35,196 shares of company stock valued at $81,001. 30.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SGHT. ProShare Advisors LLC acquired a new position in shares of Sight Sciences during the 4th quarter worth about $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sight Sciences in the 4th quarter valued at approximately $40,000. WealthTrust Asset Management LLC purchased a new stake in shares of Sight Sciences in the 4th quarter valued at approximately $48,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sight Sciences in the 4th quarter valued at approximately $50,000. Finally, Stoneridge Investment Partners LLC acquired a new position in shares of Sight Sciences in the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Sight Sciences Stock Performance

Shares of NASDAQ:SGHT traded up $0.13 during midday trading on Friday, hitting $4.02. The company had a trading volume of 343,933 shares, compared to its average volume of 215,459. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The company has a market cap of $207.82 million, a price-to-earnings ratio of -3.94 and a beta of 2.41. Sight Sciences has a 12-month low of $2.03 and a 12-month high of $8.45. The company has a fifty day moving average of $2.94 and a two-hundred day moving average of $3.08.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The firm had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. On average, equities research analysts expect that Sight Sciences will post -0.99 EPS for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.